Baiyun Mountain Annual Report Summary: 2025 Net Profit Attributable to Mother Company Increased 5.21% Year-over-Year

Radar Finance Text | Feng Xiuyu Edited | Li Yihui

On March 20th, Baiyunshan (600332) released a summary of its 2025 annual report. During the reporting period, the company achieved operating revenue of 77.656 billion yuan, a year-on-year increase of 3.55%. Net profit attributable to shareholders of the listed company was 2.983 billion yuan, up 5.21% year-on-year. After deducting non-recurring gains and losses, net profit attributable to shareholders was 2.363 billion yuan, a slight increase of 0.29%. Basic earnings per share were 1.835 yuan, up 5.21% year-on-year.

According to Tianyancha data, Baiyunshan was established on September 1, 1997, with a registered capital of 1,625,790,949 yuan. The legal representative is Li Xiaojun, and the registered address is No. 45 Shamiang North Street, Liwan District, Guangzhou. Its main business includes the research, manufacturing, and sales of Chinese and Western patent medicines, chemical raw materials, natural medicines, biopharmaceuticals, and intermediates for chemical raw materials; wholesale, retail, and import/export of Western medicines, Chinese medicines, and medical devices; research, production, and sales of health products; and investments in healthcare services, health management, wellness, and elderly care.

Currently, the company’s chairman is Li Xiaojun, the secretary of the board is Huang Xuezhen, with 27,425 employees. The actual controlling shareholder is the Guangzhou Municipal People’s Government.

The company has stakes in 146 subsidiaries, including Guangzhou Baiyunshan Baidi Biopharmaceutical Co., Ltd., Guangzhou Caizhilin Pharmaceutical Co., Ltd., Guangzhou Pharmaceutical Baiyunshan Chemical Pharmaceutical (Zhuhai) Co., Ltd., Guangzhou Qixing Pharmaceutical Co., Ltd., and Guangzhou Baiyunshan Chinese Medicine Decoction Pieces Co., Ltd.

In terms of performance, the company’s operating revenue for 2022, 2023, and 2024 was 70.788 billion yuan, 75.515 billion yuan, and 74.993 billion yuan, respectively, with year-on-year growth rates of 2.57%, 6.68%, and -0.69%. Net profit attributable to the parent was 3.967 billion yuan, 4.056 billion yuan, and 2.835 billion yuan, with year-on-year increases of 6.63%, 2.25%, and a decrease of 30.09%. During the same period, the company’s asset-liability ratio was 54.95%, 53.33%, and 53.76%.

Regarding risks, Tianyancha information shows the company has 191 internal Tianyan risks, 1,384 surrounding risks, 146 historical risks, and 684 warning alert risks.